Who is Apnea.com?
This site is a new consumer education and sleep testing initiative of Sleep Solutions, Inc., who is dedicated to helping the millions of Americans who live with the problem of Obstructive Sleep Apnea -- but who have not been diagnosed so they can receive the necessary treatment.
Sleep Solutions is working with the private insurance industry, the government and public health organizations who are very concerned about the large numbers of Sleep Apnea patients who are getting sicker each day and are using more and more healthcare resources. This, of course, is driving up healthcare expenses and the insurance rates for everyone.
By getting people diagnosed earlier, and promptly receiving treatment, not only are people's lives improved, but also healthcare costs can be held down.
Our company is honored to have been supported by a number of private individuals, venture capital firms and corporations who have provided both funding and active participation as members of our Board of Directors.
TPG Biotech
TPG Biotech is part of the venture capital investment platform of TPG, the global private investment firm. With more than $500 million under management, TPG Biotech targets investments in life science, biotechnology, renewables and medical technology companies. The firm is backed by the resources of TPG with more than $35 billion of assets under management.
www.tpgventures.com/about/tpgb.html,
www.tpg.com
Johnson & Johnson Development Corporation
As a division of the one of the world's leading medical and consumer
products companies, the Johnson & Johnson Development Corporation (JJDC)
provides funding for companies with innovative devices and therapies,
biotechnology products, and advanced pharmaceuticals.
Johnson & Johnson has $41.9 billion in sales and is the world's most
comprehensive and broadly based manufacturer of health care products,
as well as a provider of related services, for the consumer,
pharmaceutical, and medical devices and diagnostics markets. Johnson &
Johnson has approximately 110,600 employees and more than 200
operating companies in 57 countries, selling products throughout the
world.
The Johnson & Johnson Development Corporation makes equity investments
in early-stage venture and young publicly-traded health care
companies. Portfolio companies include those in the fields of
pharmaceuticals, biotechnology, medical and surgical devices, health
care information technology, diagnostics and consumer products. JJDC
also leads and manages internal investments in selected promising
technologies.
www.jnj.com,
www.jjdevcorp.com/index.jsp
MedVenture Associates
Founded in 1986, MedVenture Associates (MVA) is a private venture capital firm
specializing in the field of medical technology, including medical devices,
instrumentation and medical diagnostic technology. The firm's secondary
investment focus is medical information technology, pharmaceutical and
biotechnology products and selected later stage investments in all of the
firm's areas of investment focus. Investments are made in those areas where the
goal is to create significant, substantial new businesses.
Returns to MVA I and MVA II limited partners have been in the top quartile of
healthcare funds in the respective years each fund was offered. MVA III has
reached the end of its investment cycle. MVA IV started its investment cycle in March 2002.
MVA's goal is to invest in good ideas. Working in partnership with founding
entrepreneurs, MVA hopes to turn those ideas...into successful companies.
www.medven.com
Thomas J. Fogarty, MD
The archetypal physician entrepreneur, Thomas J. Fogarty, MD, has been a driving
force in medical device innovation for nearly 40 years. From his first device,
invented when he was still in college, until today, Fogarty has been a central
figure in global device innovation, with more than seventy patents and more
than thirty companies to his name and a host of distinguished awards.
Doctor Fogarty serves as Clinical
Professor of Vascular Surgery and Director of Research Development at
Stanford Medical School. He is coeditor-in-chief of the Journal of Endovascular Therapy,
serves on the editorial boards of several publications, contributed chapters
to numerous surgical textbooks and authored over 170 scientific
articles in the fields of cardiac, vascular and general surgery.
In 2000 he was awarded the $500,000 Lemelson-MIT Prize, one of the most
prestigious honors for inventors and innovators, and in 2001 he was inducted
into the National Inventors Hall of Fame.
vascular.stanford.edu/faculty/fogarty.html
